Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK2251052 After Single Ascending Dosesand Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and a Repeat Dose Study to Evaluatesupratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

NCT01495065 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01495065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01495065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK2251052 After Single Ascending Dosesand Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and a Repeat Dose Study to Evaluatesupratherapeutic Doses of IV GSK2251052 in Healthy Volunteers
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
December 19, 2011
Completion date
February 17, 2012
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired infection